GET DAILY SIGNALSActuate Therapeutics (ACTU): Q3 Earnings Outlook Centers on Cash Position and Pipeline Updates
Key Takeaways
- Actuate Therapeutics (ACTU) is expected to report its third-quarter fiscal 2026 results in mid-November, with Wall Street modeling a net loss of approximately $0.17 per share.
- As a clinical-stage biopharmaceutical company, Actuate generates no revenue, so investor attention centers on cash burn, operating expenses, and funding runway rather than sales.
- Consensus estimates for the quarter range from a loss of $0.15 to $0.21 per share, according to MarketWatch, pointing to a modest sequential narrowing of losses.
- The company's cash position of roughly $4.4 million as of June 30, 2026, has raised "going concern" questions, making any financing or partnership update the key watch item.
- Actuate's lead drug candidate, elraglusib, remains in a Phase 2 trial for metastatic pancreatic cancer, and clinical progress updates could outweigh the headline loss figure.
- For more detail, explore Actuate's Major News, Today's Price Move, Price Targets, and Forecast pages on Tickeron.
- You can also discover automated strategies by exploring Tickeron's Trending AI Robots.
Earnings Context and Why It Matters
Actuate Therapeutics (ACTU) is a clinical-stage biopharmaceutical company developing elraglusib, a glycogen synthase kinase-3 (GSK-3) inhibitor being studied in a Phase 2 trial for metastatic pancreatic ductal adenocarcinoma (mPDAC), an aggressive cancer with limited treatment options. Because the company is pre-revenue, its quarterly report is less about growth metrics and more about how efficiently it is managing capital. Prior quarters have shown a steady narrowing of net losses, yet the stock has fallen sharply over the past year amid persistent liquidity concerns. With limited cash on hand, this earnings print offers a crucial read on whether the company can continue advancing its pipeline without near-term dilution or additional financing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts do not expect Actuate to report any revenue for the third quarter of fiscal 2026, consistent with its clinical-stage status. The Wall Street consensus calls for a net loss of approximately $0.17 per share, according to MarketWatch, with individual estimates ranging from a loss of $0.15 to a loss of $0.21 per share. For context, the company reported a GAAP (Generally Accepted Accounting Principles) net loss of roughly $4.87 million, or $0.20 per share, in the second quarter of fiscal 2026, in line with expectations. The prior quarter had missed estimates by about 14%. Investors will likely focus less on the headline loss and more on cash levels, research and development spending, and any commentary on clinical timelines and financing plans.
Market Reaction and Investor Sentiment
Sentiment heading into the report is cautious. Actuate's stock has declined more than 90% over the past 52 weeks, trading well below its 52-week high, which reflects deep investor concerns about the company's cash runway and its ability to fund operations beyond the near term. With roughly $4.4 million in cash reported at the end of June 2026, management previously indicated the balance may only support operations into September 2026, amplifying the stakes of any funding announcement. At the same time, sell-side analysts maintain a generally positive longer-term view, with H.C. Wainwright reiterating a Buy rating and a $15 price target in September. The market will be watching closely for any signs of new capital, strategic partnerships, or clinical data updates that could ease near-term liquidity pressure. From what I see, the AI Trend Prediction Engine helped put the recent price action in perspective relative to similar names.
Forward Outlook and Key Factors to Monitor
The most pressing factor for investors after this report will be Actuate's liquidity position and any associated financing plans. As a pre-revenue company, the company depends on equity raises, debt, or partnerships to keep its clinical programs moving. Management commentary on how it intends to fund operations beyond the current cash balance will likely be scrutinized more than the earnings figure itself.
Clinical progress is another critical monitor. The company's lead asset, elraglusib, is being evaluated in a Phase 2 trial for metastatic pancreatic ductal adenocarcinoma. Any updates on enrollment, data readouts, or regulatory interactions could serve as meaningful catalysts, potentially reshaping the risk profile of the stock regardless of the quarterly loss.
Finally, investors should track operating expense discipline. Research and development and general and administrative costs have trended lower in recent quarters, and continued restraint would extend the runway. Broader biotech funding conditions may also influence sentiment, as sector-wide access to capital often affects how small-cap developers are valued. I’m watching this closely as the earnings approach.
Exploring Tickeron’s AI Tools
In my own research on names like Actuate, I’ve found Tickeron’s AI Screener particularly useful for quickly filtering clinical-stage biotechs by cash metrics, volatility, and technical patterns. It lets me scan thousands of stocks with customizable criteria and surface ideas that match specific risk profiles. This kind of structured view complements traditional fundamental work and helps keep the broader market context in sight without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACTU's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ACTU turned positive on November 04, 2026. Looking at past instances where ACTU's MACD turned positive, the stock continued to rise in 17 of 18 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACTU advanced for three days, in 89 of 99 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ACTU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACTU as a result. In 39 of 41 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACTU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ACTU entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.982) is normal, around the industry mean (3.498). P/E Ratio (-0.378) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. ACTU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACTU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
When Will Social Security Go Bankrupt?
What Are Index Funds? A Comprehensive Insight
What is the essence of Trickle-Down Economics, and how does it function in practice?
Tickeron’s AI Uncovers Bullish Rectangle Bottom Pattern for Starbucks (SBUX) Stock
AI Trading Bots: Top 10 Day Traders, Virtual Accounts, on January 14, 2025
General Information
Industry Biotechnology
Advertisement